Abstract 1382P
Background
LBx and TBx have complementary roles in detection of NSCLC driver alterations, such as METex14, which predicts efficacy of MET inhibitors. The only MET inhibitor trial to enroll based on prospective detection of METex14 in LBx and/or TBx is the VISION trial of tepotinib. We evaluated patient (pt) characteristics and outcomes according to METex14 positivity in LBx and/or TBx (data cut-off: Nov 20, 2022).
Methods
METex14 was centrally assessed in prescreening by NGS analysis of fresh LBx (Guardant360® or Archer®MET) and/or archival or fresh TBx (Oncomine Focus or Archer®MET). Pts in Japan could enroll based on local TBx RT-PCR via the LC-SCRUM program. Parallel LBx/TBx testing was recommended but not mandatory. Eligibility required LBx-positive (L+) and/or TBx-positive (T+) status.
Results
Of 313 pts, 208 (66.5%) were T+ and 178 (56.9%) were L+. L+ pts had worse baseline prognostic features than T+ pts, including more pts with ≥3 target lesions (27.5% vs 18.8%) or ECOG PS 1 (76.4% vs 72.1%), higher median sum of target lesion diameters (67.1 vs 55.2 mm) and worse health-related quality of life (mean EORTC QLQ-C30 GHS, 53.9 vs 60.1). In 180 T+ pts with matching LBx results, METex14 was detected in ctDNA (L+) in 74 (41.1%) (i.e. T+/L+) and was undetectable (L–) in 106 (58.9%) (i.e. T+/L–). ORRs were slightly higher in T+/L+ pts, but T+/L– pts had longer DOR, PFS and OS. Overall meaningful durable efficacy was seen in treatment-naive and previously treated pts (Table).
Conclusions
Tepotinib had robust and durable activity in T+ pts with L– or L+ status. While both LBx and TBx are suitable and complementary for detecting METex14, LBx may preferentially select pts with a poorer prognosis and higher tumor load. Undetectable METex14 in baseline ctDNA may define a more favorable treatment outcome. Differences in populations identified by TBx and LBx should be considered when interpreting trial data. Table: 1382P
Treatment-naive | Previously treated | |||
T+/L– (n=52) | T+/L+ (n=42) | T+/L– (n=54) | T+/L+ (n=32) | |
ORR, % (95% CI) | 57.7 (43.2, 71.3) | 64.3 (48.0, 78.4) | 44.4 (30.9, 58.6) | 53.1 (34.7, 70.9) |
mDOR, months (95% CI) | ne (10.4, ne) | 19.4 (7.6, ne) | 12.6 (5.1, 20.8) | 9.9 (4.4, 15.4) |
mPFS, months (95% CI) | 22.1 (14.8, ne) | 12.1 (7.8, 49.7) | 13.8 (8.2, 24.9) | 8.2 (5.5, 13.7) |
mOS, months (95% CI) | 32.7 (15.3, ne) | 28.5 (14.2, ne) | 20.8 (15.6, 32.5) | 19.8 (10.0, 26.5) |
CI, confidence interval; DOR, duration of response; m, median; ORR, objective response rate; OS, overall survival; PFS, progression-free survival.
Clinical trial identification
NCT02864992.
Editorial acknowledgement
Medical writing assistance (funded by Merck Healthcare KGaA, Darmstadt, Germany) was provided by Mark Dyson, DPhil (Berlin, Germany) on behalf of Syneos Health, London, UK.
Legal entity responsible for the study
Merck Healthcare KGaA, Darmstadt, Germany.
Funding
Merck Healthcare KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).
Disclosure
C.D. Rolfo: Financial Interests, Personal, Research Grant: Pfizer, Merck Sharpe & Dohme; Financial Interests, Personal, Other, consulting fees: Archer, Inivata, Bristol Myers Squibb, Novartis, Boston Pharmaceuticals, EMD Serono, an affiliate of Merck KGaA; Financial Interests, Personal, Other support: AstraZeneca, Roche, Guardant Health, Merck Sharpe & Dohme; Financial Interests, Personal, Other, safety monitoring board: EMD Serono, an affiliate of Merck KGaA; Financial Interests, Personal, Other, Leadership: International Society of Liquid Biopsy (ISLB), International Association for the Study of Lung Cancer (IASLC), European Society for Medical Oncology (ESMO). A.M. OBrate Grupp, C. Menzel, D. Juraeva, C. Stroh: Financial Interests, Personal, Full or part-time Employment: Merck Healthcare KGaA, Darmstadt, Germany. R. Bruns: Financial Interests, Personal, Full or part-time Employment: Merck Healthcare KGaA, Darmstadt, Germany; Financial Interests, Personal, Stocks/Shares: Merck Healthcare KGaA, Darmstadt, Germany. A. Johne: Financial Interests, Personal, Full or part-time Employment: Merck Healthcare KGaA, Darmstadt, Germany; Financial Interests, Personal, Stocks/Shares: Novartis. P.K. Paik: Financial Interests, Personal, Advisory Role: Takeda, Xencor, CrownBio, Bicara, Mirati, EMD Serono, an affiliate of Merck KGaA; Financial Interests, Institutional, Research Grant: Bicara, Calithera, EMD Serono, an affiliate of Merck KGaA.
Resources from the same session
1443P - Patient-reported outcomes (PROs) with cemiplimab plus chemotherapy (CEMI + CHEMO) for first-line treatment of advanced non-small cell lung cancer (aNSCLC): PD-L1 level subgroups in EMPOWER-Lung 3
Presenter: Miranda Gogishvili
Session: Poster session 20
1444P - Sintilimab with two cycles nab-paclitaxel / platinum as first line therapy for advanced squamous non-small-cell lung cancer: The final analysis and biomarker results
Presenter: Huijuan Wang
Session: Poster session 20
1445P - A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
Presenter: Ilias Houda
Session: Poster session 20
1447P - IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Presenter: Mauricio Burotto
Session: Poster session 20
1449P - The preliminary data from a single-arm, open-label, multicenter phase II clinical trial: KN046 combined with axitinib as first-line (1L) treatment for NSCLC
Presenter: Yuanyuan Zhao
Session: Poster session 20
1450P - Addition of bevacizumab to first-line chemoimmunotherapy in NSCLC with liver metastases
Presenter: Matthieu Roulleaux Dugage
Session: Poster session 20
1451P - Identifying long-term responders to immune checkpoint blockade: Potential utility of serum proteomic profiling in metastatic non-small cell lung cancer
Presenter: Rafael Bach Mora
Session: Poster session 20
1452P - Factors associated with real-world (rw) outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE
Presenter: Stephen Liu
Session: Poster session 20